Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity

Abstract Background Nanomedicine has emerged as a promising strategy for cancer treatment. The most representative nanomedicine used in clinic is PEGylated liposomal doxorubicin DOXIL®, which is first FDA-approved nanomedicine. However, several shortcomings, such as low drug loading capacity, low tu...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Man Kyu Shim, Suah Yang, Jooho Park, Jun Sik Yoon, Jinseong Kim, Yujeong Moon, Nayeon Shim, Mihee Jo, Yongwhan Choi, Kwangmeyung Kim
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	BMC 2022-10-01
Cyfres:	Journal of Nanobiotechnology
Pynciau:	Preclinical study Prodrug Nanoparticles Targeted therapy Cathepsin B Doxorubicin
Mynediad Ar-lein:	https://doi.org/10.1186/s12951-022-01644-x
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!